Amadeus-backed Fluidic Analytics has developed a machine that could help speed up the search for treatments for COVID-19. The Fluidity One-W Serum instrument provides insights into the antibody response to COVID 19 that cannot easily be obtained with traditional tests. In a matter of minutes, it allows researchers to test different types of antibodies and distinguish which are most effective at protecting us from infection. The BBC spent a day at Fluidic Analytics’ laboratories in Cambridge to see a demo of the Fluidity One-W Serum and to discuss with CEO Andrew Lynn the significance of the instrument and how it could help in the race to find an effective treatment for COVID-19.
Fluidic Analytics and the fight against Covid-19
![](https://www.amadeuscapital.com/wp-content/uploads/2020/10/Andrew-Lynn-BBC-Interview-Oct-2020-cropped-for-website-432x432-1603875672.png)